Leveraging a human-integrated mouse organoid platform to identify ERBB signalling as a target in β-catenin mutation-driven hepatocellular carcinoma

Background Although the repertoire of systemic therapies for advanced hepatocellular carcinoma (HCC) continues to expand, patient outcomes remain highly variable and often suboptimal. Emerging evidence suggests that treatment efficacy is significantly influenced by the underlying disease aetiology and specific genetic mutations. Objective Developing scalable preclinical models that accurately reflect human HCC subtypes to advance precision medicine in HCC. Design We employed HCC tumours induced via hydrodynamic tail vein injection of various proto-oncogene and tumour suppressor gene combinations in mice, complemented by a tumour organoid platform, to explore drug repurposing strategies by leveraging driver mutations as biomarkers and to characterise the features of HCC driven by distinct genetic alterations. Results High-throughput screening identified ERBB family inhibitors as promising therapeutic candidates for CTNNB1 mutation-driven HCC. Multi-omics analyses, including chromatin accessibility, transcriptomics and phosphoproteomics, revealed that CTNNB1 mutations upregulate FOXA2 expression, which functions as a transcriptional activator of ERBB signalling-related genes such as EGFR and TGFA, thereby activating the ERBB pathway. Clinically, patients with HCC harbouring CTNNB1 mutations displayed increased FOXA2 expression and ERBB pathway activation. As a proof of concept, treatment with ERBB inhibitors effectively suppressed tumour growth in vivo in mouse models and ex vivo in patient-derived organoids, specifically in HCC driven by CTNNB1 mutations but not in tumours with TP53 mutations. Conclusion Our findings uncover a novel mechanism by which β-catenin activates ERBB signalling in HCC and provide a foundation for repurposing existing drugs, such as gefitinib or afatinib, as targeted therapies for patients with CTNNB1-mutant HCC.

Authors

Institutions

Publication Details

Journal
Gut
Published
2026-11-17
DOI
https://doi.org/10.1136/gutjnl-2025-337370
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Leveraging a human-integrated mouse organoid platform to identify ERBB signalling as a target in β-catenin mutation-driven hepatocellular carcinoma

Mingdan Deng, Tin Lok Wong, 吴焕文, Stephen Li et al.
Gut
Hepatocellular Carcinoma Treatment and Prognosis
article

Leveraging a human-integrated mouse organoid platform to identify ERBB signalling as a target in β-catenin mutation-driven hepatocellular carcinoma

Mingdan Deng, Tin Lok Wong, 吴焕文, Stephen Li, Huajian Yu, Stephanie Ma, Yalin Tu, Jason W.H. Wong, Ernesto Guccione, Lei Zhou, Yan Shu Kong, Yiling Zhang, Alfred Sze‐Lok Cheng, Frank Fonseca, Ianto Bosheng Huang, Hiu Yat Yu, Jiayan Tan
article en

Abstract

Background Although the repertoire of systemic therapies for advanced hepatocellular carcinoma (HCC) continues to expand, patient outcomes remain highly variable and often suboptimal. Emerging evidence suggests that treatment efficacy is significantly influenced by the underlying disease aetiology and specific genetic mutations. Objective Developing scalable preclinical models that accurately reflect human HCC subtypes to advance precision medicine in HCC. Design We employed HCC tumours induced via hydrodynamic tail vein injection of various proto-oncogene and tumour suppressor gene combinations in mice, complemented by a tumour organoid platform, to explore drug repurposing strategies by leveraging driver mutations as biomarkers and to characterise the features of HCC driven by distinct genetic alterations. Results High-throughput screening identified ERBB family inhibitors as promising therapeutic candidates for CTNNB1 mutation-driven HCC. Multi-omics analyses, including chromatin accessibility, transcriptomics and phosphoproteomics, revealed that CTNNB1 mutations upregulate FOXA2 expression, which functions as a transcriptional activator of ERBB signalling-related genes such as EGFR and TGFA, thereby activating the ERBB pathway. Clinically, patients with HCC harbouring CTNNB1 mutations displayed increased FOXA2 expression and ERBB pathway activation. As a proof of concept, treatment with ERBB inhibitors effectively suppressed tumour growth in vivo in mouse models and ex vivo in patient-derived organoids, specifically in HCC driven by CTNNB1 mutations but not in tumours with TP53 mutations. Conclusion Our findings uncover a novel mechanism by which β-catenin activates ERBB signalling in HCC and provide a foundation for repurposing existing drugs, such as gefitinib or afatinib, as targeted therapies for patients with CTNNB1-mutant HCC.

Gut
Sun Yat-sen University (CN), Chinese University of Hong Kong (HK), The First Affiliated Hospital, Sun Yat-sen University (CN), University of Hong Kong - Shenzhen Hospital (CN), Tisch Cancer Institute (US), University of Hong Kong (HK), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon